Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
440.00    -9.20 (-2.05%)
Bid:
441.60
Ask:
441.90
Spread: 0.30 (0.068%)
Market Cap: £11.07b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Directorate Change

25 Nov 2024 07:00

RNS Number : 4179N
Rentokil Initial PLC
25 November 2024
 

 

Directorate Change: Rentokil Initial plc appoints Paul Edgecliffe-Johnson as new Chief Financial Officer. Current CFO Stuart Ingall-Tombs to retire.

 

Rentokil Initial plc (FTSE: RTO, "the Company") today announces that Paul Edgecliffe-Johnson will join the Board as Chief Financial Officer on 1 January 2025, succeeding Stuart Ingall-Tombs, who is retiring and will step down from the Board on 31 December 2024 after 17 years with the Company, most recently as Chief Financial Officer for 4 years.

 

Paul Edgecliffe-Johnson brings 25 years' experience in finance and international businesses, having most recently been CFO and a member of the Board at Flutter Entertainment PLC. Prior to that he was CFO, Group Head of Strategy, and member of the Board and Executive Committee at InterContinental Hotels Group PLC ("IHG"). Before joining IHG in 2004, Paul was an Associate Director, Corporate Finance at HSBC Holdings PLC.

 

Paul will join the Company on 1 December 2024 as CFO Designate as part of the transition process. Following 1 January 2025, Stuart will continue to be available to support a smooth handover to Paul, including assisting with the completion of the Company's financial statements for the year ending 31 December 2024.

 

Richard Solomons, Chair, said:

 

"We are delighted to announce the appointment of Paul as the Company's new Chief Financial Officer. After a robust selection process, we are confident that he possesses the right skills and experience needed to lead our financial operations and deliver business success. He is a seasoned financial executive with over a decade of company CFO experience, including at IHG where we worked together. Paul has a proven track record of driving profitable growth, optimising financial performance and implementing strategic initiatives.

 

"On behalf of the Board, I would like to thank Stuart for his contributions to Rentokil Initial over many years of committed service and to wish him a happy and healthy retirement."

 

Andy Ransom, Chief Executive, said:

 

"I would like to thank Stuart for his unwavering commitment to Rentokil Initial over the 17 years he has been with the Company. I wish him all the best and hope he has a wonderful time in his retirement.

 

"I am delighted that we have appointed Paul as Chief Financial Officer. He has an exceptional track record and reputation, and I am confident he will make a significant impact in this critical role. I am really looking forward to us working together, as his breadth of experience, along with the insights and guidance he will bring, will be invaluable as we continue to execute our Right Way Strategy in North America and across the rest of the Group."

 

Paul Edgecliffe-Johnson said:

 

"I am excited to join the talented team at Rentokil Initial and to contribute to the growth journey of this global leader. I look forward to leveraging my experience, while maintaining a strong focus on operational excellence, financial discipline and value creation."

 

 

 

Notes:

 

1. Stuart Ingall-Tombs will be treated as a good leaver by reason of his retirement for the purposes of annual bonus and awards under the Deferred Bonus Plan and Performance Share Plan in accordance with the Company's Directors' Remuneration Policy and the relevant plan rules. Further details will be disclosed on the Company's website in due course in compliance with Section 430(2B) of the Companies Act 2006, and details will also be disclosed in the Directors' Remuneration Report within the Company's Annual Report and Accounts for the year ending 31 December 2024.

2. There are no further details to be disclosed relating to Paul Edgecliffe-Johnson under Listing Rule 6.4.8.

 

 

Enquiries:

 

Investors / Analysts: Peter Russell, Rentokil Initial plc: + 44(0)7795166506

Media: Malcolm Padley, Rentokil Initial plc: +44(0)7788978199

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPGRUGUPCGUC
Date   Source Headline
31st Mar 20211:16 pmRNSTotal Voting Rights
31st Mar 202110:33 amRNSAnnual Financial Report
30th Mar 20216:23 pmRNSDirector Declaration
24th Mar 20215:55 pmRNSDirector/PDMR Shareholding
12th Mar 20219:00 amRNSAdditional Listing
4th Mar 20217:05 amRNSDirectorate Change
4th Mar 20217:00 amRNSFinal Results
17th Feb 20215:45 pmRNSDirector Declaration
8th Jan 20217:00 amRNSQ4 2020 Acquisitions and Trading Update
27th Nov 20202:25 pmBUSEarly Repurchase(s)
27th Nov 20202:22 pmBUSEarly Repurchase(s)
24th Nov 20205:25 pmRNSDirector/PDMR Shareholding
20th Nov 20207:00 amRNSResult of Tender Offer for Notes due 2021
12th Nov 20209:02 amRNSTender Offer for Notes due 2021
22nd Oct 20207:00 amRNSQ3 Trading Update
8th Oct 20207:00 amRNSSuccessful EUR600m 8-year bond transaction priced
1st Oct 20209:00 amRNSBlock listing Interim Review
28th Aug 20203:40 pmRNSDirector/PDMR Shareholding
7th Aug 20205:24 pmRNSDirector/PDMR Shareholding
30th Jul 20207:00 amRNSInterim Results
6th Jul 20207:00 amRNSDirectorate Change
21st May 202011:00 amRNSDirector/PDMR Shareholding
13th May 20205:15 pmRNSResult of AGM
7th May 20204:45 pmRNSDirector/PDMR Shareholding
27th Apr 20203:50 pmRNSDisclosure of Rights Attached to Equity Shares
17th Apr 202011:59 amRNSDirector/PDMR Shareholding
16th Apr 20207:00 amRNSQ1 Trading Update
14th Apr 20205:26 pmRNSHolding(s) in Company
9th Apr 20204:35 pmRNSDirector/PDMR Shareholding
2nd Apr 20201:36 pmRNSDirector/PDMR Shareholding
1st Apr 20205:33 pmRNSConfirmation of Non-Executive Director Appointment
1st Apr 20209:24 amRNSBlock listing Interim Review
31st Mar 20202:18 pmRNSTotal Voting Rights
30th Mar 202012:37 pmRNSRedemption of 4.5% debenture stock
30th Mar 202012:24 pmRNSRedemption of 5% debenture stock
27th Mar 202011:00 amRNSHolding(s) in Company
26th Mar 20204:41 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
26th Mar 202011:29 amRNSAnnual Financial Report
25th Mar 20207:00 amRNSTrading Update
19th Mar 202011:30 amRNSDirector Declaration
17th Mar 20201:15 pmRNSAdditional Listing
6th Mar 202012:00 pmRNSHolding(s) in Company
27th Feb 20207:05 amRNSDirectorate Change
27th Feb 20207:00 amRNSFinal Results
21st Feb 20204:00 pmRNSHolding(s) in Company
24th Dec 20191:10 pmRNSHolding(s) in Company
19th Dec 20192:40 pmRNSDirector/PDMR Shareholding
17th Dec 20195:10 pmRNSHolding(s) in Company
26th Nov 20196:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.